Ebymect 5 mg/850 mg, filmomhulde tabletten

About this medicine
Details marketing authorisation

This medicine has been approved for use for the indication as stated here. Availability: Uitsluitend recept

About this medicine

Active substance:	DAPAGLIFLOZINEPROPAANDIOL 1-WATER 6.15 mg/stuk SAMENSTELLING overeenkomend met DAPAGLIFLOZINE 5 mg/stuk METFORMINEHYDROCHLORIDE 850 mg/stuk SAMENSTELLING overeenkomend met METFORMINE 662.7 mg/stuk
Excipients:	CELLULOSE, MICROKRISTALLIJN (E 460(i)) HYPROLOSE (E 463) IJZEROXIDE GEEL (E 172) IJZEROXIDE ROOD (E 172) MACROGOL 3350 MAGNESIUMSTEARAAT (E 470b) NATRIUMZETMEELGLYCOLAAT POLYVINYLALCOHOL (E 1203) TALK (E 553b) TITAANDIOXIDE (E 171)

externe link Information about Metformin and dapagliflozin on Farmacotherapeutisch Kompas

SmPC, label and patient information leaflet

Alert: this document may contain the product information for several strengths and/or pharmaceutical forms.

Product page on the website of the European Medicines Agency

Patient information

You can find an extensive description of the efficacy and possible adverse events of this medicine in the patient information leaflet and summary of the product characteristics.

Patient information

externe link Information about Metformin and dapagliflozin on Lareb.nl

Are you experiencing adverse events? Please report to the Adverse Events Centre Lareb. externe link I would like to report an adverse event

Do you need more information on sickness and health? Take a look at externe link Thuisarts.nl.

News 12 november 2021

Patient information

You can find an extensive description of the efficacy and possible adverse events of this medicine in the patient information leaflet and summary of the product characteristics.